Clinical trials: Solid Tumor, completed
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
- Trial name
- NCT05700669
- Testing
- AsiDNA, Olaparib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Valerio Therapeutics
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer
This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis
- Trial name
- NCT05878405
- Testing
- Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse, Methylene Blue Oral Rinse
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Melanoma, Non-small Cell Lung Cancer
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04609566
- Testing
- brentuximab vedotin, pembrolizumab
- Where
- 90 sites in United States
- Volunteers
- 161 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Cancer
Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System
This is an open-label, three-parallel group pharmacokinetic study. Patients with advanced solid tumors will be assigned to one of three groups to receive I.V. doses of eribulin (E7389).
- Trial name
- NCT00706095
- Testing
- E7389
- Where
- 2 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- Eisai Inc.
Neoplasms
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the…
- Trial name
- NCT03521037
- Testing
- Rucaparib camsylate
- Where
- 6 sites in Poland, Slovakia and 1 more
- Volunteers
- 16 people
- Sponsor
- pharmaand GmbH
Neurotoxicity, Pain
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
RATIONALE: Topical cream containing amitriptyline and ketamine may help relieve pain, numbness, tingling, and other symptoms of peripheral neuropathy.
- Conditions
- Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00471445
- Testing
- ketamine/amitriptyline NP-H cream
- Where
- 17 sites in United States
- Volunteers
- 462 people
- Sponsor
- Gary Morrow
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
- Trial name
- NCT02482311
- Testing
- AZD 1775
- Where
- 16 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT05694364
- Testing
- Fludarabine, Cyclophosphamide, PRGN-3007
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced/Metastatic Solid Tumors
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG116-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
- Trial name
- NCT05277402
- Testing
- ADG116
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adagene Inc
Cachexia, Fatigue
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
RATIONALE: Megestrol helps improve appetite. Exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. Exercise plus megestrol may be effective treatment for cancer-related weight loss.
- Conditions
- Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004912
- Testing
- megestrol acetate, physical therapy
- Where
- 6 sites in United States
- Sponsor
- Northwestern University
Tumor, Solid
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT04196530)
- Testing
- BDB001 (EIK1001), Atezolizumab
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eikon Therapeutics
Malignancies
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.
- Trial name
- NCT01407380
- Testing
- PWT33597 mesylate
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pathway Therapeutics, Inc.
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
MDM2/MDMX Gene Mutation, Nuclear Medicine
First Human Trial of Targeting MDM2/MDMX PET Imaging
Investigation of the Radiotracer Uptake of [68Ga] MDM2/MDMX Peptide at Lesion Sites in Patients with Malignant Tumors, and Evaluation of the Capability of [68Ga] MDM2/MDMX Peptide to Detect Overexpression of MDM2/MDMX in Tumor…
- Conditions
- MDM2/MDMX Gene Mutation, Nuclear Medicine, Positron Emission Tomography Imaing
- Trial name
- NCT06443762
- Testing
- [68Ga] MDM2/MDMX Peptide
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University Cancer Hospital & Institute
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00929903
- Testing
- pazopanib hydrochloride, pharmacological study
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Relapsed Tumors, Refractory Solid Tumors
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
- Trial name
- NCT02482441
- Testing
- OMP-131R10, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00058253
- Testing
- tanespimycin, docetaxel
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer. PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or preventing…
- Trial name
- IRB 2003-551 (NCT00064272)
- Testing
- ginger extract
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.